Yeah I take your point and agree that anything less then a deal to get this into a phase 3 trial would most likely result in a substantial negative reaction based on market expectation created from Biotron's commentary.
In regards to the patent expiration:
1 - I believe there are laws in both the US and Aus that allow for pharmaceutical companies to apply for extensions for their IP, 2-5 years from memory.
2- Regardless of the patent life - If Biotron's IP adds value that current drugs do not and there is a demand for the compound it is irrelevant that a Pharma may try drag out the deal for their own benefit as others will snatch it up as they won't risk losing this. I think it all depends on the value of their IP. Only the potential partners and Pharmas will be privy to this.
I have to say they seem extremely confident that they will get Commercialisation outcomes.
It will be very interesting to see what the next chapter of this story tells.
My guess is the ducks will line up on this one!
AIMO
Yeah I take your point and agree that anything less then a...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
